Article

Phase 3 Checkmate-025, Evaluating Nivolumab in RCC, Stopped Early

Author(s):

Nivolumab proved superior to everolimus in improving overall survival in previously treated patients.

In a press release from earlier today, Bristol Myer's Squibb, the developer of nivolumab, announced that the phase 3 Checkmate-025 trial was halted early by an independent Data Monitoring Committee following significantly better overall survival of patients receiving nivolumab, compared with the control. The trial was evaluating the efficacy of nivolumab versus everolimus in previously treated renal cell carcinoma patients.

“Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb.

Read the complete press release here: http://bit.ly/1LxXiK6

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
1 expert in this video
1 expert in this video
Dr Mingyang Song
Casey Koch, PharmD, sitting for a video interview
1 expert in this video
1 expert in this video
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo